FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

[1]  J. Ambati,et al.  Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor 1* , 2008, Journal of Biological Chemistry.

[2]  Zhen-ping Zhu,et al.  VEGF signaling on hematopoietic precursors restricts B-lymphoid commitment in vitro and in vivo. , 2008, Experimental hematology.

[3]  P. Carmeliet,et al.  Beneficial effects of prolonged systemic administration of PlGF on late outcome of post‐ischaemic myocardial performance , 2008, The Journal of pathology.

[4]  Fabian Kiessling,et al.  Flt-1 signaling in macrophages promotes glioma growth in vivo. , 2008, Cancer research.

[5]  T. Fujii,et al.  VEGF function for upregulation of endogenous PlGF expression during FGF-2-mediated therapeutic angiogenesis. , 2008, Atherosclerosis.

[6]  A. Tramontano,et al.  Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide. , 2008, European journal of cancer.

[7]  C. Gargioli,et al.  PlGF–MMP-9–expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle , 2008, Nature Medicine.

[8]  M. Kanda,et al.  Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico‐pathological parameters , 2008, Journal of surgical oncology.

[9]  P. Carmeliet,et al.  Reevaluation of the Role of VEGF-B Suggests a Restricted Role in the Revascularization of the Ischemic Myocardium , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[10]  D. Hanahan,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[11]  Chiun Hsu,et al.  Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer , 2008, Pancreas.

[12]  M. Michaelson,et al.  Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[14]  D. Ribatti.  The discovery of the placental growth factor and its role in angiogenesis: a historical review , 2008, Angiogenesis.

[15]  J. Angus,et al.  Vascular Effects of FGF-2 and VEGF-B in Rabbits with Bilateral Hind Limb Ischemia , 2008, Journal of Vascular Research.

[16]  Victoria L. Bautch,et al.  The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching , 2008, The Journal of cell biology.

[17]  J. Fleming,et al.  Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. , 2008, Cancer research.

[18]  M. Shibuya,et al.  Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase , 2008, Japanese Journal of Ophthalmology.

[19]  Yasufumi Sato.  VEGFR1 for lymphangiogenesis: an alternative signaling pathway? , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[20]  M. Shibuya,et al.  VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage Recruitment , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[21]  C. Alpers,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[22]  S. Horiuchi,et al.  Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. , 2008, Diabetes research and clinical practice.

[23]  C. Rocha-Lima,et al.  New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. , 2008, The oncologist.

[24]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[25]  Yu-Chih Liang,et al.  Placental growth factor down‐regulates type 1 T helper immune response by modulating the function of dendritic cells , 2007, Journal of leukocyte biology.

[26]  G. Kay,et al.  Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model. , 2007, Rheumatology.

[27]  G. Yancopoulos,et al.  VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade , 2007, Proceedings of the National Academy of Sciences.

[28]  G. Christofori,et al.  Placental Growth Factor-1 Attenuates Vascular Endothelial Growth Factor-A–Dependent Tumor Angiogenesis during β Cell Carcinogenesis , 2007 .

[29]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[30]  P. Carmeliet,et al.  Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. , 2007, The Journal of clinical investigation.

[31]  J. Christensen,et al.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy , 2007, Proceedings of the National Academy of Sciences.

[32]  R. Jain,et al.  Down-Regulation of Placenta Growth Factor by Promoter Hypermethylation in Human Lung and Colon Carcinoma , 2007, Molecular Cancer Research.

[33]  Kenneth P. Roos,et al.  Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.

[34]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[35]  Dale Edwards,et al.  Ginkgo biloba and ovarian cancer prevention: epidemiological and biological evidence. , 2007, Cancer letters.

[36]  M. Ho,et al.  Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. , 2007, Cancer letters.

[37]  H. Verheul,et al.  Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition , 2007, Nature Reviews Cancer.

[38]  M. Shibuya,et al.  Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting , 2007, The Journal of experimental medicine.

[39]  D. Hicklin,et al.  Simultaneous blockade of VEGFR‐1 and VEGFR‐2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation , 2007, International journal of cancer.

[40]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[41]  P. Carmeliet,et al.  Genetic Deletion of Placenta Growth Factor in Mice Alters Uterine NK Cells , 2007, The Journal of Immunology.

[42]  I. Giannopoulou,et al.  The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. , 2007, Gynecologic oncology.

[43]  R. Tepper,et al.  Cyclic stretch induces PlGF expression in bronchial airway epithelial cells via nitric oxide release. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[44]  Alice P. Taylor,et al.  Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts , 2007, Molecular Cancer Therapeutics.

[45]  F. Mascarelli,et al.  Placental growth factor-1 and epithelial haemato–retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy , 2007, Diabetologia.

[46]  F. Colotta,et al.  Placental Growth Factor‐1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony‐Stimulating Factor in Mice and Nonhuman Primates , 2007, Stem cells.

[47]  J. Pollard,et al.  Macrophages regulate the angiogenic switch in a mouse model of breast cancer. , 2006, Cancer research.

[48]  M. Kreuter,et al.  Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia , 2006, Leukemia.

[49]  M. Berry,et al.  Placental Growth Factor Provides a Novel Local Angiogenic Therapy for Ischemic Cardiomyopathy , 2006, Journal of cardiac surgery.

[50]  D. Hicklin,et al.  Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer , 2006, Clinical Cancer Research.

[51]  S. Rafii,et al.  The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma , 2006, International journal of cancer.

[52]  F. Sera,et al.  Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. , 2006, The American journal of pathology.

[53]  P. Carmeliet,et al.  Impaired Adipose Tissue Development in Mice With Inactivation of Placental Growth Factor Function , 2006, Diabetes.

[54]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[55]  M. Shibuya,et al.  Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. , 2006, Blood.

[56]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[57]  A. Ciucci,et al.  Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. , 2006, The American journal of pathology.

[58]  K. Uematsu,et al.  Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. , 2006, Lung cancer.

[59]  Peter Carmeliet,et al.  VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  P. Wiedemann,et al.  Human retinal epithelium produces and responds to placenta growth factor , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[61]  Geert Carmeliet,et al.  Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repair. , 2006, The Journal of clinical investigation.

[62]  Ricky T. Tong,et al.  Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. , 2006, Cancer research.

[63]  T. Mikawa,et al.  VEGF Family Members Regulate Myocardial Tubulogenesis and Coronary Artery Formation in the Embryo , 2006, Circulation research.

[64]  Limor Chen,et al.  Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. , 2006, Cancer research.

[65]  H. Augustin,et al.  The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms. , 2006, Blood.

[66]  Zhen-ping Zhu,et al.  VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. , 2006, Blood.

[67]  A. Nash,et al.  The biology of vascular endothelial growth factor-B (VEGF-B). , 2006, Pulmonary pharmacology & therapeutics.

[68]  Betty Y. Y. Tam,et al.  VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. , 2006, American journal of physiology. Heart and circulatory physiology.

[69]  C. Kuo,et al.  Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. , 2006, American journal of physiology. Heart and circulatory physiology.

[70]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[71]  F. Peale,et al.  Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. , 2006, Blood.

[72]  K. Jin,et al.  Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. , 2006, Developmental biology.

[73]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[74]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[75]  P. Carmeliet,et al.  Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. , 2005, Human gene therapy.

[76]  Jun Cai,et al.  Placenta growth factor is over-expressed and has prognostic value in human breast cancer. , 2005, European journal of cancer.

[77]  A. Pospischil,et al.  Immunohistochemical study about the Flt-1/VEGFR1 expression in the gastrointestinal tract of mouse, rat, dog, swine and monkey. , 2005, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[78]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  R. Mansel,et al.  Expression of Placenta growth factor (PlGF) in non-Small cell Lung cancer (NSCLC) and the clinical and prognostic significance , 2005, World journal of surgical oncology.

[80]  A. Parenti,et al.  Intracellular pathways triggered by the selective FLT‐1‐agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia , 2005, British journal of pharmacology.

[81]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[82]  I. Constable,et al.  Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  G. Kay,et al.  Transgenic Overexpression of Vascular Endothelial Growth Factor-B Isoforms by Endothelial Cells Potentiates Postnatal Vessel Growth In Vivo and In Vitro , 2005, Circulation research.

[84]  Roberto Torella,et al.  Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. , 2005, Journal of the American College of Cardiology.

[85]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[86]  K. Alitalo,et al.  Gene Transfers of Vascular Endothelial Growth Factor-A, Vascular Endothelial Growth Factor-B, Vascular Endothelial Growth Factor-C, and Vascular Endothelial Growth Factor-D Have No Effects on Atherosclerosis in Hypercholesterolemic Low-Density Lipoprotein-Receptor/Apolipoprotein B48-Deficient Mice , 2005, Circulation.

[87]  Christoph Dehio,et al.  VEGF-A and PlGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. , 2005, Biochemical and biophysical research communications.

[88]  A. Luttun,et al.  Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and Macrophage Accumulation , 2005, Circulation.

[89]  M. Vieth,et al.  Epithelial cells disseminate into the bone marrow of colorectal adenoma patients , 2005, Gut.

[90]  Lee M Ellis,et al.  Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells , 2005, Oncogene.

[91]  Ge Li,et al.  Anti-Flt1 Peptide, a Vascular Endothelial Growth Factor Receptor 1–Specific Hexapeptide, Inhibits Tumor Growth and Metastasis , 2005, Clinical Cancer Research.

[92]  E. Duh,et al.  Upregulation of placental growth factor by vascular endothelial growth factor via a post‐transcriptional mechanism , 2005, FEBS letters.

[93]  N. Funata,et al.  Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer , 2005, British Journal of Cancer.

[94]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[95]  K. Sunagawa,et al.  Essential Role of Vascular Endothelial Growth Factor and Flt-1 Signals in Neointimal Formation After Periadventitial Injury , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[96]  F. De Ceuninck,et al.  The inflammatory side of human chondrocytes unveiled by antibody microarrays. , 2004, Biochemical and biophysical research communications.

[97]  King-Jen Chang,et al.  The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. , 2004, Cancer letters.

[98]  Yihai Cao,et al.  Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion , 2004, Circulation research.

[99]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[100]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[101]  E. Estey,et al.  Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes , 2004, Cancer.

[102]  Jingtai Cao,et al.  VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. , 2004, The Journal of clinical investigation.

[103]  C. Dehio,et al.  Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion. , 2004, Cardiovascular research.

[104]  Masato Nakamura,et al.  Overexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma. , 2004, Anticancer research.

[105]  V. Alakhov,et al.  A Vascular Endothelial Growth Factor High Affinity Receptor 1-specific Peptide with Antiangiogenic Activity Identified Using a Phage Display Peptide Library* , 2003, Journal of Biological Chemistry.

[106]  P. Bohlen,et al.  Blockade of Vascular Endothelial Growth Factor Receptor I (VEGF-RI), but not VEGF-RII, Suppresses Joint Destruction in the K/BxN Model of Rheumatoid Arthritis 1 , 2003, The Journal of Immunology.

[107]  M. Feldmann,et al.  Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis , 2003, Gene Therapy.

[108]  H. Yamanaka,et al.  Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. , 2003, Anticancer research.

[109]  K. Alitalo,et al.  Angiogenic responses of vascular endothelial growth factors in periadventitial tissue. , 2003, Human gene therapy.

[110]  P. Oettgen,et al.  Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids , 2003, Current Biology.

[111]  K. Seuwen,et al.  Bone morphogenetic protein 2 induces placental growth factor in mesenchymal stem cells. , 2003, Bone.

[112]  G. Kay,et al.  Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. , 2003, Arthritis and rheumatism.

[113]  N. Perelman,et al.  Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. , 2003, Blood.

[114]  B. Lévy,et al.  Vascular Endothelial Growth Factor‐B Promotes In Vivo Angiogenesis , 2003, Circulation research.

[115]  Christoph Dehio,et al.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.

[116]  Lois E. H. Smith,et al.  Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. , 2003, The Journal of clinical investigation.

[117]  J. Rakic,et al.  Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.

[118]  Alice P. Taylor,et al.  Altered tumor vessel maturation and proliferation in placenta growth factor‐producing tumors: Potential relationship to post‐therapy tumor angiogenesis and recurrence , 2003, International journal of cancer.

[119]  Stephen B Fox,et al.  The angiogenic switch for vascular endothelial growth factor (VEGF)‐A, VEGF‐B, VEGF‐C, and VEGF‐D in the adenoma–carcinoma sequence during colorectal cancer progression , 2003, The Journal of pathology.

[120]  S. Eddahibi,et al.  Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[121]  F. Larcher,et al.  Modulation of the angiogenesis response through Ha‐ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis , 2003, Molecular carcinogenesis.

[122]  R. Kauppinen,et al.  VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses , 2003, Circulation research.

[123]  S. Rafii,et al.  Angiogenic Factors Reconstitute Hematopoiesis by Recruiting Stem Cells from Bone Marrow Microenvironment , 2003, Annals of the New York Academy of Sciences.

[124]  P. Carmeliet,et al.  VEGFR-1–Selective VEGF Homologue PlGF Is Arteriogenic: Evidence for a Monocyte-Mediated Mechanism , 2003, Circulation research.

[125]  Alan W. Stitt,et al.  Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression. , 2003, Investigative ophthalmology & visual science.

[126]  G. Kay,et al.  Vascular endothelial growth factor‐B and retinal vascular development in the mouse , 2003, Clinical & experimental ophthalmology.

[127]  T. H. van der Kwast,et al.  Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma , 2003, Journal of clinical pathology.

[128]  A. Luttun,et al.  Bone marrow transplantation abolishes inhibition of arteriogenesis in placenta growth factor (PlGF) -/- mice. , 2003, Journal of molecular and cellular cardiology.

[129]  P. Carmeliet,et al.  A critical role of placental growth factor in the induction of inflammation and edema formation. , 2003, Blood.

[130]  H. Kuwano,et al.  Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. , 2002, Anticancer research.

[131]  M. Shibuya,et al.  Vascular Endothelial Growth Factor Receptor Family Genes: When Did the Three Genes Phylogenetically Segregate? , 2002, Biological chemistry.

[132]  M. Shibuya,et al.  MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. , 2002, Cancer cell.

[133]  K. Alitalo,et al.  Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. , 2002, The American journal of pathology.

[134]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[135]  G. Kay,et al.  Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. , 2002, Cardiovascular research.

[136]  A. Luttun,et al.  Loss of placental growth factor protects mice against vascular permeability in pathological conditions. , 2002, Biochemical and biophysical research communications.

[137]  S. Wiegand,et al.  Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. , 2002, Endocrinology.

[138]  S. Rafii,et al.  Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.

[139]  G. Vrensen,et al.  Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[140]  L. Benjamin,et al.  Placental growth factor is a survival factor for tumor endothelial cells and macrophages. , 2002, Cancer research.

[141]  M. Shibuya,et al.  Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. , 2002, Molecular cancer therapeutics.

[142]  Yihai Cao,et al.  Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. , 2002, Cancer Cell.

[143]  D. Horsfall,et al.  A potential autocrine role for vascular endothelial growth factor in prostate cancer. , 2002, Cancer research.

[144]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[145]  K. Alitalo,et al.  Vascular Endothelial Growth Factor-B–Deficient Mice Display an Atrial Conduction Defect , 2001, Circulation.

[146]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[147]  S. Fox,et al.  Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. , 2001, Cancer research.

[148]  F. Sellke,et al.  Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia. , 2001, The Journal of thoracic and cardiovascular surgery.

[149]  W. Schaffner,et al.  Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. , 2001, Cancer research.

[150]  N. Ferrara,et al.  Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) , 2001, The Journal of Biological Chemistry.

[151]  T. Noda,et al.  Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. , 2001, Cancer research.

[152]  Xuri Li,et al.  Isoform-specific Expression of VEGF-B in Normal Tissues and Tumors , 2001, Growth factors.

[153]  K. Matsumoto,et al.  Extracellular matrix tenascin‐X in combination with vascular endothelial growth factor B enhances endothelial cell proliferation , 2000, Genes to cells : devoted to molecular & cellular mechanisms.

[154]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[155]  H. Traxler,et al.  Selective Downregulation of VEGF-A165, VEGF-R1, and Decreased Capillary Density in Patients With Dilative but Not Ischemic Cardiomyopathy , 2000, Circulation research.

[156]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[157]  G. Zambruno,et al.  Placenta growth factor is induced in human keratinocytes during wound healing. , 2000, The Journal of investigative dermatology.

[158]  N. Ferrara,et al.  A repressor sequence in the juxtamembrane domain of Flt‐1 (VEGFR‐1) constitutively inhibits vascular endothelial growth factor‐dependent phosphatidylinositol 3′‐kinase activation and endothelial cell migration , 2000, The EMBO journal.

[159]  L. Gnudi,et al.  Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. , 2000, Journal of the American Society of Nephrology : JASN.

[160]  S. Hirohashi,et al.  Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[161]  S. Grimm,et al.  Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[162]  A. Eggert,et al.  High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[163]  J. Vaillant,et al.  Vegf, vegf‐B, vegf‐C and their receptors KDR, FLT‐1 and FLT‐4 during the neoplastic progression of human colonic mucosa , 2000, International journal of cancer.

[164]  G. Kay,et al.  Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. , 2000, Circulation research.

[165]  M. Nomura,et al.  Placenta Growth Factor and Vascular Endothelial Growth Factor B and C Expression in Microvascular Endothelial Cells and Pericytes , 1999, The Journal of Biological Chemistry.

[166]  K. Plate,et al.  Expression and localization of placenta growth factor and PlGF receptors in human meningiomas , 1999, The Journal of pathology.

[167]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[168]  T. Yamashima,et al.  Placenta growth factor (PlGF) mRNA expression in brain tumors , 1998, Journal of Neuro-Oncology.

[169]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[170]  M. Shibuya,et al.  Neuropilin-1 Is a Placenta Growth Factor-2 Receptor* , 1998, The Journal of Biological Chemistry.

[171]  T. Noda,et al.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[172]  K.,et al.  Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[173]  M. Shibuya,et al.  Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials , 1998, Oncogene.

[174]  Kenneth J. Hillan,et al.  Vascular endothelial growth factor is essential for corpus luteum angiogenesis , 1998, Nature Medicine.

[175]  A. N. Corps,et al.  Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[176]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[177]  H. Granger,et al.  Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[178]  J. Folkman,et al.  In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. , 1996, The Journal of clinical investigation.

[179]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[180]  G. Breier,et al.  The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities , 1996, The Journal of Biological Chemistry.

[181]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[182]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[183]  K. Alitalo,et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[184]  B. Keyt,et al.  Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors , 1996, The Journal of Biological Chemistry.

[185]  K. Alitalo,et al.  Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. , 1996, The American journal of pathology.

[186]  M. Shibuya,et al.  Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[187]  G. Viglietto,et al.  Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. , 1995, Oncogene.

[188]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[189]  M. Shibuya,et al.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.

[190]  K. Plate,et al.  Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanisms , 1994, International journal of cancer.

[191]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[192]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[193]  A. Ullrich,et al.  Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.

[194]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[195]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[196]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.

[197]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[198]  G. Zambruno,et al.  The placenta growth factor in skin angiogenesis. , 2006, Journal of dermatological science.

[199]  B. Gigante,et al.  The FASEB JournalFJ Express Full Length Article Plgf / eNos / mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia , 2006 .

[200]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[201]  B. Gigante,et al.  Placenta growth factor is not required for exercise-induced angiogenesis , 2004, Angiogenesis.

[202]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[203]  B. Tom,et al.  Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF , 2004, Angiogenesis.

[204]  K. Nakashiro,et al.  Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. , 2004, Oral oncology.

[205]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[206]  G. Neufeld,et al.  The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. , 2002, Advances in experimental medicine and biology.

[207]  M. Shibuya,et al.  Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. , 2001, Human pathology.

[208]  M. Persico.  Placenta Growth Factor , 2001 .

[209]  V. Vincenti,et al.  Structure, expression and receptor-binding properties of placenta growth factor (PlGF). , 1999, Current topics in microbiology and immunology.

[210]  B. Olffson.  Vascular endothelial grouth facter B, a novel growth facter for endothelial cells , 1996 .

[211]  D. Maglione.  Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .